Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC).

Burger, Robert A.; Brady, M. F.; Rhee, Joon Haeng; Sovak, Mika A.; Nguyen, Hoang-Nam; Bookman, M. A.

doi:10.1200/jco.2011.29.15_suppl.5023

Cited by 7 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four of the references were conference abstracts that described RCTs that fulfilled our criteria. Three of these were studies that had completed primary data collection (Burger 2010 (GOG-0218); Karlan 2010; Ledermann 2009). One study was still ongoing at the time of finding the most recent abstract using our search strategy (Mazur 2006, subsidiary reference to Perren 2010 (ICON7)); however, further handsearching and contacting of investigators identified that results had recently been reported at a conference (Perren 2010 (ICON7)).…”

Section: Resultsmentioning

confidence: 99%

“…The Burger 2010 (GOG-0218) trial had multiple treatment groups (three-arm trial), and so we divided the control group between the treatment groups, and treated comparisons between each treatment group and a split control group as independent comparisons for all adverse event outcomes. This was not necessary for OS as we obtained HR estimates from a Cox regression model.…”

Section: Methodsmentioning

confidence: 99%

“…On the basis of success from these studies, phase III trials have been performed combining bevacizumab with carboplatin and taxol chemotherapy in postoperative patients with ovarian cancer in the GOG 218 (Burger 2010 (GOG-0218)) and the ICON 7 (Perren 2010 (ICON7)) study. These trials are also assessing the role of bevacizumab in the maintenance treatment of these patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Angiogenesis inhibitors for the treatment of ovarian cancer

Gaitskell

Martinek

Bryant

et al. 2011

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being developed to target specific molecular pathways. One such class of drugs inhibits angiogenesis (the development of new blood vessels), which is essential for tumour growth. It is important to establish whether the addition of these new drugs to conventional chemotherapy regimens improves survival, and what the side-effects may be. Objectives To compare the effectiveness and toxicities of angiogenesis inhibitors in the treatment of ovarian cancer. Search methods We sought to identify completed randomised controlled trials (RCTs) by searching The Cochrane Gynaecological Cancer Review Group’s Trial Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 10), MEDLINE and EMBASE (1990 to October 2010). We also searched registers of clinical trials, and contacted investigators of completed and ongoing trials for further information. Selection criteria Randomised controlled studies comparing angiogenesis inhibitors with either standard chemotherapy or no treatment, in women with ovarian cancer. Data collection and analysis Two independent authors carried out data collection and extraction. We used a random-effects model for pooling data. Main results We did not find any fully-published, completed RCTs of angiogenesis inhibitors that met our inclusion criteria. We identified five abstracts of completed RCTs of four different angiogenesis-inhibiting agents, with a total of 3701 participants. Meta-analysis of two trials found no statistically significant difference in overall survival (OS) between women with newly-diagnosed advanced ovarian cancer who received concurrent and maintenance bevacizumab compared to those who received chemotherapy (carboplatin and paclitaxel) alone. However, women who received concurrent and maintenance bevacizumab had their risk of disease progression reduced by a quarter (hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.68 to 0.83; P < 0.001); they also had a significantly increased risk of severe gastrointestinal adverse events, moderate or severe hypertension and severe bleeding. One trial also compared chemotherapy to concurrent (but not maintenance bevacizumab), and found no statistically significant difference in OS or progression-free survival (PFS). However, the women who received bevacizumab had a significantly higher risk of moderate or severe hypertension. A three-armed RCT, of paclitaxel alone or with low- or high-dose AMG 386, in women with recurrent ovarian cancer, found no statistically significant difference in OS. However, women who received low-dose AMG 386 had a third less risk of disease progression than those who received placebo (HR 0.57, 95% CI 0.36 to 0.91; P = 0.02). The trial found no evidence of increased adverse events in the intervention arms. Two relatively small RCTs (one of VEGF-Trap, the other of BIBF 1120) found no evidence of either significant survival benefi...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Angiogenesis inhibitors for the treatment of ovarian cancer

Gaitskell

Martinek

Bryant

et al. 2011

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…Substanz parallel oder sequenziell testen sollten, hatten für die Patientinnen keinen Benefit ergeben, allerdings eine deutlich höhere Toxizität. Erst der zusätzliche Einsatz des Antiangiogenese-Antikörpers Bevacizumab hatte zu einer Verbesserung des Gesamtüberlebens geführt, allerdings nur in den fortgeschrittenen Tumorstadien FIGO IIIB und IV [3][4][5]. Die seit 2012 bestehende Zulassung für die Primärtherapie war ein weiterer Meilenstein in der Primärbehandlung des Ovarialkarzinoms.…”

unclassified

Systemtherapie des Ovarialkarzinoms

Grischke¹,

Kommoss²,

Taran³

2017

Frauenheilkunde up2date

View full text Add to dashboard Cite

“…Pour ce sous-groupe était constatée une augmentation significative de la SSP de 12 à 18 mois (p > 0,0001). Ces résultats ont été actualisés lors du congrès de Chicago 2011, avec notamment une évaluation indépendante [7] Les études GOG 218 et ICON 7 sont différentes en plusieurs points : les critères d'inclusion, l'utilisation d'un placebo, la dose et la durée du bevacizumab. La progression n'était pas évaluée de la même manière dans les deux études.…”

unclassified

Gynaecological cancers

Petit¹

2011

Oncologie

View full text Add to dashboard Cite

Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC).

Cited by 7 publications

References 0 publications

Angiogenesis inhibitors for the treatment of ovarian cancer

Angiogenesis inhibitors for the treatment of ovarian cancer

Systemtherapie des Ovarialkarzinoms

Gynaecological cancers

Contact Info

Product

Resources

About